Poseida Therapeutics, Inc. Common Stock
PSTX
PSTX was delisted on the 7th of January, 2025.
0 hedge funds and large institutions have $0 invested in Poseida Therapeutics, Inc. Common Stock in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.
100% less funds holding
Funds holding: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $308K → $0 (-$308K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
|
-$308K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
DekaBank Deutsche Girozentrale
Frankfurt,
Germany
| – | -$308K | -100,000 | Closed |
|
PSTX Hedge Fund Activity: Q2 2025 in Review
0 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2025, worth a combined $0 — down 100% from $308K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of PSTX and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.
The largest seller was DekaBank Deutsche Girozentrale, exiting entirely with an estimated $308K sold.
- 0 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2025, down from 1 in Q1 2025.
- Funds reported $0 of Poseida Therapeutics, Inc. Common Stock stock for Q2 2025, down 100% quarter-over-quarter.
- 0 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2025 was DekaBank Deutsche Girozentrale, an estimated $308K sold.
Based on aggregated 13F filings for Q2 2025.